China's BeiGene Attracts Global Investments For Cancer Research
This article was originally published in PharmAsia News
Executive Summary
China's biotech BeiGene has received financial backing from U.S.-based Merck and is discussing similar investments by seven other pharmaceuticals to help it attack cancer in China